Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep 27;3(4):52.
doi: 10.3390/jof3040052.

The Role of IL-17 in Protection against Mucosal Candida Infections

Bemnet G Mengesha  1 , Heather R Conti  2
Affiliations
Review

The Role of IL-17 in Protection against Mucosal Candida Infections

Bemnet G Mengesha et al. J Fungi (Basel). .

Abstract

Interleukin-17 (IL-17) is a proinflammatory cytokine produced by adaptive CD4+ T helper cells and innate lymphocytes, such as γδ-T cells and TCRβ+ "natural" Th17 cells. IL-17 activates signaling through the IL-17 receptor, which induces other proinflammatory cytokines, antimicrobial peptides and neutrophil chemokines that are important for antifungal activity. The importance of IL-17 in protective antifungal immunity is evident in mice and humans, where various genetic defects related to the IL-17-signaling pathway render them highly susceptible to forms of candidiasis such oropharyngeal candidiasis (OPC) or more broadly chronic mucocutaneous candidiasis (CMC), both caused mainly by the opportunistic fungal pathogen Candida albicans. OPC is common in infants and the elderly, HIV/AIDS and patients receiving chemotherapy and/or radiotherapy for head and neck cancers. This review focuses on the role of IL-17 in protection against candidiasis, and includes a brief discussion of non-Candida albicans fungal infections, as well as how therapeutic interventions blocking IL-17-related components can affect antifungal immunity.

Keywords: C. albicans; chronic mucocutaneous candidiasis; mucosal fungal infections; oropharyngeal candidiasis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Brown G.D., Denning D.W., Gow N.A., Levitz S.M., Netea M.G., White T.C. Hidden killers: Human fungal infections. Sci. Transl. Med. 2012;4:165rv113. doi: 10.1126/scitranslmed.3004404. - DOI - PubMed
    1. Erjavec Z., Kluin-Nelemans H., Verweij P.E. Trends in invasive fungal infections, with emphasis on invasive aspergillosis. Clin. Microbiol. Infect. 2009;15:625–633. doi: 10.1111/j.1469-0691.2009.02929.x. - DOI - PubMed
    1. Garber G. An overview of fungal infections. Drugs. 2001;61(Suppl. 1):1–12. doi: 10.2165/00003495-200161001-00001. - DOI - PubMed
    1. Pfaller M.A., Diekema D.J. Epidemiology of invasive candidiasis: A persistent public health problem. Clin. Microbiol. Rev. 2007;20:133–163. doi: 10.1128/CMR.00029-06. - DOI - PMC - PubMed
    1. Bishu S., Su E.W., Wilkerson E.R., Reckley K.A., Jones D.M., McGeachy M.J., Gaffen S.L., Levesque M.C. Rheumatoid arthritis patients exhibit impaired candida albicans-specific Th17 responses. Arthritis Res. Ther. 2014;16:R50. doi: 10.1186/ar4480. - DOI - PMC - PubMed

LinkOut - more resources